on NOVACYT (EPA:ALNOV)
Novacyt announces its preliminary results for 2025
Novacyt SA has released its preliminary unaudited results for fiscal year 2025, with figures in line with market expectations. Statutory revenue reached approximately £20 million, representing a 4% increase year-over-year. This growth was driven by strong development in the instrumentation sector, particularly with the LightBench® Discover instrument, and solid performance of NIPT technologies in the clinical sector.
The APAC region contributed significantly to this growth, with a 10% increase in revenue. Despite a slight decline in the RUO segment, the company maintained a strong cash position of £19.2 million without resorting to debt. Novacyt is counting on a promising project pipeline to continue this momentum into 2026.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all NOVACYT news